Iveric Bio's Izervay (avacincaptad pegol intravitreal solution) Receives the US FDA’s Approval for the Treatment of Geographic Atrophy
Shots:
- The US FDA has approved Izervay (complement C5 inhibitor) for the treatment of GA secondary to AMD. The therapy is expected to be available in the US in 2-4wks.
- The approval was based on the P-III trials (GATHER1 & 2) evaluating Izervay (2mg, qm, IVT) in 286 & 448 patients, which showed a significant reduction in the rate of GA progression over sham at 12mos. across two P-III clinical trials & slowed loss of photoreceptors and disease progression as early as 6mos. with ~35% reduction in 1yr. of treatment
- Additionally, the most common adverse reactions (≥ 5%) were reported at 12mos. across the (GATHER) clinical trial program in patients who received Izervay (2mg)
Ref: prnewswire | Image: Iveric Bio
Rewlated News:- Iveric Bio Reports the US FDA Acceptance of NDA and Granted Priority Review of Avacincaptad Pegol for Geographic Atrophy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
